Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardima to begin Phase III US trial for AF (atrial fibrillation) catheter:

This article was originally published in Clinica

Executive Summary

Cardima has received permission from the US FDA to begin the pivotal Phase III stage of its clinical trial to assess its Revelation Tx microcatheter-based ablation device for treating paroxysmal atrial fibrillation (AF). Data from Phase I and II of the US trial and from European trials and commercial use of the product indicate that about 80% of patients treated with the microcatheter have experienced either total elimination or a significant reduction in their AF, said Fremont, California-based Cardima. The product is already CE-marked for sale in Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel